Navigation Links
The Hepatitis C virus is the main cause of liver transplant in the world
Date:7/25/2014

ion is in most of the cases asymptomatic and it leads to a chronic infection in 80% of the cases. Of these patients, 20% develop hepatic cirrhosis, which is the previous step to hepatic failure. Of these 20%, from 3% to 5% develop liver cancer.

Not treating the illness may lead to complications that in an important number of patients may lead to the necessity of a liver transplant.  The transplant has additional complications of serious considerations, such as the availability of the organs, the high costs associated to it and the required post-transplant care. This may have severe consequences for the patients as well as for the public health systems.

The paradigm of the Hepatitis C treatment has changed, above all, starting with the arrival of therapeutic alternatives that directly attack the virus, increasing cure rates. We are facing a new era.   Medications that change the regimen of treatment and management of Hepatitis C with higher cure rates in patients infected with HCV (Hepatitis C Virus) genotype 1, which is most predominant genotype in our environment and the most resistant to treatments.

The main goal of the Hepatitis C treatment is to accomplish a sustained viral response (SVR); this means that the virus remains undetectable in the patient´s blood (known as undetectable viral load) six months after finishing the treatment[3]. The patients that achieve an SVR are considered cured.

Telaprevir is part of the Direct-Acting Antivirals (DAAs), which are medications directed to specific enzymes to block important stages of the Hepatitis C virus replication. The DAAs have the potential to help the patients achieve a sustained viral response (SVR).

Telaprevir is a protease inhibitor that is used for only 12 weeks, in all cases, offering this way, a short duration treatment for the patients.

This new therapeutic alternative, presented by the pharmaceutical laboratory Janssen, offers the possibilit
'/>"/>

SOURCE Janssen
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CVS Caremark JAMA Commentary: New Hepatitis C Treatments Highlight Need to Control Costs of High-Priced Specialty Medications
2. Sinovac Receives Tender to Supply Inactivated Hepatitis A Vaccine Healive in Beijing Under Expanded Immunization Program
3. State Governments May Spend $55 Billion on Hepatitis C Medications
4. Decision Resources to Publish Reports That Include Market Analysis and a Forecast through 2022 for the Hepatitis C Virus and Hospital-Treated Bacterial Infections Drug Markets
5. American Liver Foundation Hails Promise of Cure Signaled by FDAs Approval of New Hepatitis C Treatments
6. AbbVie Demonstrates 96 percent SVR(12) in its Phase III Study of Treatment-Experienced Patients with Genotype 1 Hepatitis C
7. Giant Eagle Expands Specialty Pharmacy with Acquisition, Bringing Treatment Expertise to Customers with Hepatitis C and Organ Transplant Conditions
8. Despite Increasing Cost Sensitivity of EU5 Payers, Sofosbuvir and Simeprevir are Poised to Reshape the Hepatitis C Virus Market by End of 2015
9. Behandlungsbefürworter fechten Patent für neues Hepatitis C Medikament an
10. Treatment Advocates Challenge Patent for New Hepatitis C Drug
11. Current Hepatitis C Virus Regimens to Face Stiff Competition with the Launch of Gileads Sofosbuvir and Janssen/Medivirs Simeprevir
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Sept. 17, 2014 Bronstein, Gewirtz & Grossman, ... of the securities of PDL BioPharma, Inc. ("PDL BioPharma" ... Such investors are advised to contact Peretz Bronstein ... at info@bgandg.com or 212-697-6484. ... of its executives violated federal securities laws. ...
(Date:9/17/2014)... September 17, 2014 ... has shown positive data in a Phase 2a proof ... , Glenmark Pharmaceuticals today announced ... 1 (TRPA1) antagonist, GRC 17536 has shown positive data ... proof of concept study conducted on 138 patients in ...
(Date:9/17/2014)... 2014   MedeAnalytics today unveils Revenue ... complete visibility to a provider,s "mid-cycle" to optimize ... landscape. Powered by the industry,s leading big data ... point between patient access and the business office ... improve revenue capture, minimize audit risk and prepare ...
Breaking Medicine Technology:Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 3MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3
... New study finds patients who opt for surgery have decreased pain, ... with the spine disease called degenerative spondylolisthesis * ... pain over time compared to those who do not have surgery, ... The Journal of Bone and Joint Surgery ...
... GAITHERSBURG, Md., June 1 Overall survival data in ... GenVec,s ongoing Phase III Pancreatic Cancer Clinical Trial with ... Society of Clinical Oncology Annual Meeting in Orlando, FL. ... ) , , The poster ...
Cached Medicine Technology:Back to Normal: Surgery Improves Outcomes for Spine Patients 2Back to Normal: Surgery Improves Outcomes for Spine Patients 3Back to Normal: Surgery Improves Outcomes for Spine Patients 4TNFerade(TM) Phase III Data Presented at ASCO 2TNFerade(TM) Phase III Data Presented at ASCO 3
(Date:9/17/2014)... Asian Americans at higher risk of developing type 2 ... disease at lower body weights? One part of this ... low-fat Asian diets to current westernized diets, which may ... George King, M.D., Senior Vice President and Chief Scientific ... of the study. , A Joslin randomized clinical trial ...
(Date:9/17/2014)... The in vitro diagnostics (IVD) marketplace ... focusing on molecular diagnostics for conditions such as infectious ... The IVD market value is projected to be worth ... The major drivers of the market’s growth include the ... evidenced by the explosion for raid and minimally-invasive diagnostic ...
(Date:9/17/2014)... HealthDay Reporter WEDNESDAY, Sept. 17, 2014 ... explain why antibiotic-resistant bacteria can thrive in a hospital setting. ... be the culprit. They can easily enter bacteria and move ... that makes bacteria drug-resistant, a new study finds. "The ... a class of antibiotic called carbapenems," said the study,s co-author, ...
(Date:9/17/2014)... Research has shown that most 18-month-olds learn an average ... little is known about how children process information to ... years. In a new study, a University of Missouri ... they age, and a limit exists as to how ... could help parents enhance their children,s vocabularies and assist ...
(Date:9/17/2014)... September 17, 2014 Celestix Networks, ... solutions, today announced that it will launch a ... 2014. This new offering will provide seamless Active ... Software-as-a-Service applications to enable secure single sign-on and ... of cloud computing, there has been a dramatic ...
Breaking Medicine News(10 mins):Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 2Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 3Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 2Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 3Health News:Researchers Discover How Bacteria Resist Antibiotics in Hospitals 2Health News:Researchers Discover How Bacteria Resist Antibiotics in Hospitals 3Health News:Babies learn words differently as they age, researcher finds 2Health News:Celestix Announces Availability of ADFS Bridge Appliance in October 2014 to Simplify the Configuration of Office 365 with Active Directory 2
... , WEDNESDAY, Feb. 9 (HealthDay News) -- The number ... attempts swings sharply depending on what month it is, a ... for men aged 50 and older, while there was little ... the report from the Substance Abuse and Mental Health Services ...
... many patients realise that diabetes can affect their kidneys is ... multi-cultural study in the March issue of the Journal ... to 48 patients with diabetes attending specialist renal services in ... risks posed by the disease was very low. ...
... Researchers from the Hospital Virgen de las Nieves of ... frequent mutations in the gene KCNH2 in patients with long ... cardiac ionic channels that approximately affects one in every 2,500 ... trigger sudden death. This condition usually affects children and adolescents, ...
... Sciences Discovery Fund (LSDF) today announced nearly $600,000 in ... the diagnosis and management of major health conditions. ... producing novel tests to diagnose or monitor disease. Jane ... a Washington-based company, will adapt a novel air sampling ...
... HealthDay Reporter , TUESDAY, Feb. 8 (HealthDay News) -- Men ... bearing children with congenital problems such as a cleft palate compared ... research. But the overall risk was low, researchers from Sweden ... of the National Cancer Institute . And the findings ...
... at the University at Buffalo have devised two new ... important molecules from losing their shape and degrading in ... the development of peptide-based drugs against diseases including cancer. ... than existing techniques, one of which employs an expensive ...
Cached Medicine News:Health News:Males' Drug-Related Suicide Attempts Vary by Month 2Health News:Experts call for greater awareness of the links between diabetes and kidney disease 2Health News:Experts call for greater awareness of the links between diabetes and kidney disease 3Health News:Researchers identify the genotype of disorders causing cardiac sudden death syndrome 2Health News:Washington Life Sciences Discovery Fund announces grants to commercialize promising technologies 2Health News:Washington Life Sciences Discovery Fund announces grants to commercialize promising technologies 3Health News:Birth Defect Risk Slightly Higher for Kids of Male Cancer Survivors 2Health News:Birth Defect Risk Slightly Higher for Kids of Male Cancer Survivors 3Health News:New techniques for stapling peptides could spur development of drugs for cancer 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: